President & Chief Executive Officer (CEO)
Jonas has worked for over 25 years in the Life Science sector. He is an associate professor of pharmacology at Uppsala University and has a B.Sci in chemistry from Stockholm University, a PhD in experimental neurology from Uppsala University and has been a postdoctoral fellow at the University of Southern California (USC), School of Pharmacy. He has trained in strategic planning and business leadership. Previously, he has held management roles in companies in Sweden, Switzerland and USA. Most recently, Jonas was CEO of the Swiss biotechnology company BOWS Pharmaceuticals SA; before that he was active in companies such as Pharmacia, Biovitrum, Sequenom and Invitrogen. Jonas has worked as CEO of the Group since 2010 (between 2015 and 2017, on a consulting basis). He has been employed as CEO since 2017.
Other assignments: Board director of CombiGene AB, Pergamum AB and Pergasus AB.
Holding in Promore Pharma: 51,666 shares.
Chief Financial Officer (CFO)
Erik has more than 25 years of experience as an economist, including as a financial analyst and partner at ABG Sundal Collier, as CFO at the biotechnology company SentoClone AB, and as a senior business controller at Capio, Aleris, Systembolaget and Coop Online AB. Erik became the company’s CFO in August 2020.
Other assignments: Erik is the managing director of his own consulting company Råderik AB and CFO at Emplicure AB (publ).
Holding in Promore Pharma: 82,982 shares.
Chief Scientific Officer (CSO)
Margit has more than 15 years of experience in research and development of pharmaceutical products. She previously worked at AstraZeneca, Arexis and Swedish Orphan Biovitrum, among others. Margit is a professor of molecular medicine at the University of Gothenburg. She has a PhD in molecular and cell biology from the University of Gothenburg. She started within the Group in 2007 as responsible for regulatory strategy and clinical development.
Other assignments: Margit is a board member of Sixera Pharma AB and is chairman of the board and managing director of her own companies ScandiCure AB and Alexera AB. She is a board member and managing director of her own consulting company Arexela AB.
Holding in Promore Pharma: No current holding.
Holdings as of December 31, 2022.